1 reports of this reaction
1.8% of all CALENDULA OFFICINALIS reports
#6 most reported adverse reaction
APPLICATION SITE BURN is the #6 most commonly reported adverse reaction for CALENDULA OFFICINALIS, manufactured by Seroyal USA. There are 1 FDA adverse event reports linking CALENDULA OFFICINALIS to APPLICATION SITE BURN. This represents approximately 1.8% of all 56 adverse event reports for this drug.
Patients taking CALENDULA OFFICINALIS who experience application site burn should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
APPLICATION SITE BURN is a less commonly reported adverse event for CALENDULA OFFICINALIS, but still significant enough to appear in the safety profile.
In addition to application site burn, the following adverse reactions have been reported for CALENDULA OFFICINALIS:
The following drugs have also been linked to application site burn in FDA adverse event reports:
APPLICATION SITE BURN has been reported as an adverse event in 1 FDA reports for CALENDULA OFFICINALIS. This does not prove causation, but indicates an association observed in post-market surveillance data.
APPLICATION SITE BURN accounts for approximately 1.8% of all adverse event reports for CALENDULA OFFICINALIS, making it a notable side effect.
If you experience application site burn while taking CALENDULA OFFICINALIS, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.